To date, metformin remains the first-line oral glucose-lowering drug used for the treatment of
type 2 diabetes thanks to its well-established long-term safety and efficacy profile. Indeed …

Metformin blocks the absorption of vitamin B12 through a mechanism that has not been
established but could be because of interference with the calcium‐dependent binding of the …

Context: Vitamin B12 deficiency may occur with metformin treatment, but few studies have
assessed risk with long-term use. Objective: To assess the risk of B12 deficiency with …

People with type 2 diabetes form a heterogeneous group. Consequently, treatment
regimens and therapeutic targets should be individualized. The treatment of type 2 diabetes …

People with elevated, non-diabetic, levels of blood glucose are at risk of progressing to
clinical type 2 diabetes and are commonly termed 'prediabetic'. The term prediabetes …

Aim Metformin is the most widely used oral hypoglycaemic drug, but it may lower B 12
status, which could have important clinical implications. We undertook a systematic review …

Diabetes is accompanied by several complications. Higher prevalence of cancers,
cardiovascular diseases, chronic kidney disease (CKD), obesity, osteoporosis, and …

Background Metformin is first‐line therapy for patients with diabetes. However, it may lower
vitamin B12 concentrations, which could have hematological or neurological implications …

Background and aims Metformin-treated type 2 diabetes mellitus (T2DM) patients are at
higher risk of vitamin B 12 deficiency and more severe neuropathy symptoms. There is still …

Apart from being a safe, effective and globally affordable glucose-lowering agent for the
treatment of diabetes, metformin has earned much credit in recent years as a potential anti …